Adolescent and Adult Vaccines Market 2018 in Adults to Drive Growth

138 views

Published on

Buy the report "Adult and Adolescent Vaccines Market to 2018 – Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth" for US$3500 as a Single User PDF License from RnR Market Research Reports Library.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
138
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Adolescent and Adult Vaccines Market 2018 in Adults to Drive Growth

  1. 1. RnR Market Research Offers “Adult and Adolescent Vaccines Market to 2018 – PromisingNovel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults toDrive Growth” Report at US$ 3500. The report got published in Apr 2013.The leading business intelligence provider GBI Research has released its latest research report, entitled“Adult and Adolescent Vaccines Market to 2018”. The report provides insights into the vaccines in theadult and adolescent vaccines market, including market forecasts up to 2018. It provides an in-depthanalysis of the vaccines for the adult and adolescent market, as well as insights into the adult andadolescent vaccines market’s Research and Development (R&D) pipeline. The report provides in-depthanalysis of the unmet needs, drivers and barriers that affect the global adult and adolescent vaccinesmarket. The report analyzes the market for adult and adolescent vaccines in the US, and the top fivecountries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report discusses theglobal pipeline for adult and adolescent vaccines across various stages of development. The report isbuilt using data and information sourced from proprietary databases, primary and secondary researchand in-house analysis by GBI Research’s team of industry experts. GBI Research found that the adultand adolescent vaccines market in the top seven markets was valued at $7.2 billion in 2011, increasing ata Compound Annual Growth Rate (CAGR) of 6.9% during the 2007–2011 historic period. The market isprojected to witness a growth of 5.6% during the 2011–2018 forecast period to reach $10.5 billion. Thegrowth in the adult and adolescent vaccines market is driven by increased uptake of pneumococcalvaccines such as Prevnar 13 which got approved for use in people aged 50 and older. The pneumococcalvaccines market is expected to grow at a CAGR of 19% during the forecast period and reach $1.7 billionin 2018, from $0.5 billion in 2011.Get Complete Report Details @ http://www.rnrmarketresearch.com/adult-and-adolescent-vaccines-market-to-2018-promising-novel-candidates-in-late-stage-development-and-prevnar-approval-for-use-in-adults-to-drive-growth-market-report.htmlScope- Annualized market data for the adult and adolescent vaccines market from 2007 to 2011, forecastforward to 2018- Analysis of the adult and adolescent vaccines market in the leading geographies of the world, whichincludes the US, the UK, Germany, France, Italy, Spain, and Japan- Market characterization of the adult and adolescent vaccines market including market size and cost ofvaccination- Key drivers and barriers that have a significant impact on the market- Coverage of pipeline molecules in various phases of vaccine development- Competitive benchmarking of leading companies. Key companies studied in this report areGlaxoSmithKline, Sanofi, Pfizer, Merck and Novartis.- Key M&A activities and licensing agreements that have taken place between 2009 and up to November2012 in the global adult and adolescent vaccines market.Reasons to Buy- Align your product portfolio to the markets with the highest growth potential- Develop market-entry and market expansion strategies by identifying the potential regions and adult andadolescent vaccines market segments poised for strong growth- Create a more specifically-tailored country strategy through the understanding of key drivers andbarriers of the global adult and adolescent vaccines market
  2. 2. - Develop key strategic initiatives by understanding the key focus areas and top-selling products ofleading companies- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitionsand strategic partnerships.Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=88539Table of Content1 Table of Contents1.1 List of Tables1.2 List of Figures2 Adult and Adolescent Vaccines Market to 2018: Introduction2.1 Overview3 Adult and Adolescent Vaccines Market to 2018: Overview3.1 Vaccine Preventable Diseases3.1.1 Types of Vaccines3.2 Recommendations for Immunization3.2.1 The US3.2.2 Top Five European Countries3.2.3 Japan3.3 Regulatory Framework3.3.1 The US3.3.2 Top Five European Countries3.3.3 Japan3.4 Vaccine Manufacturing Process4 Adult and Adolescent Vaccines Market to 2018: Market Characterization and Forecast4.1 Revenue Forecast4.2 Market Share by Type of Vaccines4.3 Market Share by Geography4.4 Drivers4.4.1 Adult Vaccines Segment to Drive Future Growth4.4.2 High Unmet Needs4.4.3 Targeting New Diseases Areas for Vaccines Likely To Drive the Market4.4.4 Novel Vaccine Technologies4.5 Restraints4.5.1 Production Capacity Limitations4.5.2 High Initial Capital Investments and Technical Expertise4.5.3 Regulations Delay Vaccine Launch and Acceptance5 Adult and Adolescent Vaccines Market to 2018: Influenza Vaccines5.1 Disease Overview5.2 Market Forecasts5.2.1 The US5.2.2 Top Five European Countries5.2.3 Japan5.3 Cost of Vaccination5.3.1 The US5.3.2 Top Five European Countries5.3.3 Japan5.4 Pipeline Analysis – Influenza Vaccines6 Adult and Adolescent Vaccines Market to 2018: Tetanus, Diphtheria and Pertussis Vaccines6.1 Disease Overview
  3. 3. 6.2 Market Forecasts6.2.1 The US6.2.2 Top Five European Countries6.2.3 Japan6.3 Cost of Vaccination6.3.1 The US6.3.2 Top Five European Countries6.3.3 Japan6.4 Pipeline Analysis – Tetanus, Diphtheria, Pertussis (Td/Tdap) Vaccines7 Adult and Adolescent Vaccines Market to 2018: Pneumococcal Vaccines7.1 Disease Overview7.2 Market Forecasts7.2.1 The US7.2.2 Top Five European Countries7.2.3 Japan7.3 Cost of Vaccination7.3.1 The US7.3.2 Top Five European Countries7.3.3 Japan7.4 Pipeline Analysis – Pneumococcal Vaccines8 Adult and Adolescent Vaccines Market to 2018: Meningococcal Vaccines8.1 Disease Overview8.2 Market Forecasts8.2.1 The US8.2.2 Top Five European Countries8.3 Cost of Vaccination8.3.1 The US8.3.2 Top Five European Countries8.4 Pipeline Analysis – Meningococcal Vaccines9 Adult and Adolescent Vaccines Market to 2018: Human Papilloma Virus Vaccines9.1 Disease Overview9.2 Market Forecasts9.2.1 The US9.2.2 Top Five European Countries9.2.3 Japan9.3 Cost of Vaccination9.3.1 The US9.3.2 Top Five European Countries10 Adult and Adolescent Vaccines Market to 2018: Hepatitis Vaccines10.1 Disease Overview10.2 Market Forecasts10.2.1 The US10.2.2 Top Five European Countries10.2.3 Japan10.3 Cost of Vaccination10.3.1 The US10.3.2 Top Five European Countries11 Adult and Adolescent Vaccines Market to 2018: Measles, Mumps and Rubella Vaccines11.1 Disease Overview11.2 Market Forecasts11.2.1 The US11.2.2 Top Five European Countries
  4. 4. 11.2.3 Japan11.3 Cost of Vaccination11.3.1 The US11.3.2 Top Five European Countries11.3.3 Japan12 Adult and Adolescent Vaccines Market to 2018: Zoster Vaccines12.1 Disease Overview12.2 Market Forecasts12.2.1 The US12.2.2 The UK12.3 Cost of Vaccination12.3.1 The US12.3.2 The UK12.4 Pipeline Analysis – Zoster Vaccines13 Adult and Adolescent Vaccines Market to 2018: Varicella Vaccines13.1 Disease Overview13.2 Market Forecasts13.2.1 The US13.2.2 Top Five European Countries13.2.3 Japan13.3 Cost of Vaccination13.3.1 The US13.3.2 Top Five European Countries13.3.3 Japan13.4 Pipeline Analysis – Varicella Vaccines14 Adult and Adolescent Vaccines Market to 2018: Competitive Landscape14.1 Introduction14.2 Major Company Profiles14.2.1 GlaxoSmithKline14.2.2 Sanofi14.2.3 Pfizer14.2.4 Merck14.2.5 Novartis15 Adult and Adolescent Vaccines Market to 2018: Strategic Consolidations15.1 Deals by Year15.2 Deals by Type15.3 Deals by Value15.4 Deals by Geography15.5 Summary of Major M&A Deals15.6 Summary of Major Licensing Deals15.7 Summary of Major Partnerships16 Adult and Adolescent Vaccines Market to 2018: Appendix16.1 Market Definitions16.2 Abbreviations16.3 Bibliography16.4 Research Methodology16.4.1 Coverage16.4.2 Secondary Research16.4.3 Primary Research16.4.4 Model for Estimation of Vaccine Market16.5 Geographical Landscape16.6 Pipeline Analysis
  5. 5. For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com/

×